Physician profile
Ryan Sattar
NPI 1871151753
$6,400.78
in general payments reported to CMS, 2019-2025
22 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $1,133 · 2023: $1,653 · 2024: $1,214 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,316.43 | 2021-2025 | Fasenra, Tezspire, Symbicort |
| Glaxosmithkline, LLC. | $955.69 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $949.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $525.96 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $429.11 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $408.17 | 2022-2025 | Glassia |
| Verona Pharma, INC. | $345.10 | 2025 | Ohtuvayre |
| Insmed, INC. | $281.45 | 2021-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.44 | 2021-2024 | Ofev, Stiolto Respimat |
| Viatris Specialty LLC | $227.19 | 2025 | Yupelri |
| Amgen INC. | $149.40 | 2022-2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $119.82 | 2022 | |
| Mylan Specialty L.P. | $99.88 | 2022-2023 | Yupelri |
| Baxter Healthcare | $86.53 | 2023 | Hillrom - Life 2000 Ventilation System |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $44.74 | 2023-2025 | Opsynvi, Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $37.81 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.11 | 2023 | Acthar |
| Tactile Systems Technology INC | $25.63 | 2023 | Flexitouch Plus, Entre Plus |
| Lilly USA, LLC | $17.75 | 2025 | Zepbound |
| Philips North America LLC | $15.18 | 2022 | |
| Inogen, INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Sattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.